Atara Biotherapeutics, Inc.
NASDAQ:ATRABiotechnology
+$0.19 today
- Market cap
- $68.98M
- Beta
- 0.11
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.67
Volume 0.02M
Average 1.40M
ATRA Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Atara Biotherapeutics, Inc.NASDAQ: ATRA
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue falls 95.7% from a year ago
Deferred revenue stood at $684K at the end of Q1 FY2026, down 95.7% from a year earlier and down 4.5% from the prior quarter. Over 3 fiscal years it compounded at -55.3% a year.
Context
- Deferred revenue amounted to 3.4% of total assets at the end of Q1 FY2026, down 22.3 pp from a year earlier.
- Deferred revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred revenue keeps falling in the next quarterly balance sheet after a -95.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 716K USD
- Year-over-year change
- -99.2%
- 4-year CAGR
- -63.6%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 716K | -99.2% |
| FY2024 | 2024-12-31 | 95.09M | +22.2% |
| FY2023 | 2023-12-31 | 77.83M | +872.9% |
| FY2022 | 2022-12-31 | 8M | -80.4% |
| FY2021 | 2021-12-31 | 40.76M | — |
Deferred Revenue vs competitors
How ATRA compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -95.7% is the lowest of 6, against a peer median of -8.5%.
- Deferred revenue amounts to 3.4% of total assets for ATRA, versus a peer median of 0.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $67.99M USD | +335.3% | +3.0% | 31.2% | |
| Jan 2026 | $10M USD | -8.5% | +11.7% | 35.1% | |
| Mar 2026 | $9.4M USD | -86.4% | -14.3% | 3.9% | |
| Mar 2026 | $1.47M USD | — | +0.3% | 0.5% | |
| Mar 2026 | $1.24M USD | +47.7% | — | 2.3% | |
| Mar 2026 | $684K USD | -95.7% | -55.3% | 3.4% | |
| Mar 2026 | $219K USD | -51.9% | +42.6% | 1.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | €0 EUR | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ATRA) | — | -8.5% | +3.0% | 0.8% | |
Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 106.08M | 92.94M | 25.84M | 25.03M | 8.48M |
| Short-term Investments | 264.98M | 149.88M | 25.88M | 17.47M | 0 |
| Net Receivables | 986K | 40.22M | 34.11M | 1.48M | 1.25M |
| Inventory | 0 | 1.59M | 9.71M | 10.66M | 0 |
| Other Current Assets | 194K | 10.45M | 6.33M | 10.26M | 2.48M |
| Total Current Assets | 384.62M | 295.08M | 101.87M | 64.89M | 12.21M |
| Property, Plant & Equipment (Net) | 79.94M | 74.32M | 58.79M | 41.1M | 7.14M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.57M | 7.02M | 4.84M | 3.1M | 886K |
| Total Non-current Assets | 83.51M | 81.34M | 63.64M | 44.2M | 8.02M |
| Total Assets | 468.13M | 376.42M | 165.5M | 109.1M | 20.24M |
| Account Payables | 17.37M | 6.87M | 3.68M | 4.37M | 127K |
| Short-term Debt | 0 | 0 | 0 | 0 | 10.78M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 40.76M | 8M | 77.83M | 95.09M | 716K |
| Other Current Liabilities | 25.15M | 32.75M | 37.01M | 6.59M | 2.03M |
| Total Current Liabilities | 105.79M | 78.92M | 142.23M | 134.57M | 14.92M |
| Long-term Debt | 0 | 0 | 0 | 0 | 32.67M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 55.71M | 77M | 37.56M | 0 | 0 |
| Other Non-current Liabilities | 1.5M | 35.8M | 39.25M | 41.89M | 1.8M |
| Total Non-current Liabilities | 82.73M | 170.86M | 122.51M | 71.81M | 43.82M |
| Total Liabilities | 188.51M | 249.78M | 264.74M | 206.38M | 58.74M |
| Common Stock | 9K | 10K | 11K | 1K | 1K |
| Retained Earnings | (1.46B) | (1.69B) | (1.97B) | (2.05B) | (2.02B) |
| Accumulated OCI | (368K) | (2.07M) | (204K) | 8K | 1K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 279.61M | 126.64M | (99.23M) | (97.28M) | (38.5M) |
| Total Debt | 28.27M | 71.7M | 57.87M | 43.83M | 52.8M |
| Net Debt | (77.81M) | (21.24M) | 32.03M | 18.8M | 44.32M |
Atara Biotherapeutics, Inc.
NASDAQ:ATRA
Intrinsic Alpha fair value
Locked
Current Price
$6.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.